6/14
07:19 am
tngx
Tango Therapeutics (TNGX) Moves 10.3% Higher: Will This Strength Last? [Yahoo! Finance]
Medium
Report
Tango Therapeutics (TNGX) Moves 10.3% Higher: Will This Strength Last? [Yahoo! Finance]
6/5
07:00 am
tngx
Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Medium
Report
Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
6/4
06:30 am
tngx
Tango Therapeutics, Inc. (NASDAQ: TNGX) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
Low
Report
Tango Therapeutics, Inc. (NASDAQ: TNGX) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
5/28
08:00 am
tngx
Tango Therapeutics, Inc. (NASDAQ: TNGX) had its price target lowered by analysts at HC Wainwright from $16.00 to $13.00. They now have a "buy" rating on the stock.
Low
Report
Tango Therapeutics, Inc. (NASDAQ: TNGX) had its price target lowered by analysts at HC Wainwright from $16.00 to $13.00. They now have a "buy" rating on the stock.
5/24
01:04 pm
tngx
Tango Therapeutics, Inc. (NASDAQ: TNGX) had its price target lowered by analysts at Guggenheim from $16.00 to $14.00. They now have a "buy" rating on the stock.
Low
Report
Tango Therapeutics, Inc. (NASDAQ: TNGX) had its price target lowered by analysts at Guggenheim from $16.00 to $14.00. They now have a "buy" rating on the stock.
5/24
11:04 am
tngx
Tango Therapeutics, Inc. (NASDAQ: TNGX) had its price target lowered by analysts at Barclays PLC from $18.00 to $13.00. They now have an "overweight" rating on the stock.
Low
Report
Tango Therapeutics, Inc. (NASDAQ: TNGX) had its price target lowered by analysts at Barclays PLC from $18.00 to $13.00. They now have an "overweight" rating on the stock.
5/23
03:03 pm
tngx
Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity [Yahoo! Finance]
Low
Report
Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity [Yahoo! Finance]
5/23
01:43 pm
tngx
Tango Therapeutics, Inc. (NASDAQ: TNGX) had its price target lowered by analysts at Wedbush from $18.00 to $11.00. They now have an "outperform" rating on the stock.
Medium
Report
Tango Therapeutics, Inc. (NASDAQ: TNGX) had its price target lowered by analysts at Wedbush from $18.00 to $11.00. They now have an "outperform" rating on the stock.
5/23
09:34 am
tngx
Medivir's licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program [Yahoo! Finance]
Medium
Report
Medivir's licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program [Yahoo! Finance]
5/23
09:18 am
tngx
Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program
Medium
Report
Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program
5/23
07:07 am
tngx
Tango Therapeutics Announces Discontinuation of TNG348 Program [Yahoo! Finance]
Medium
Report
Tango Therapeutics Announces Discontinuation of TNG348 Program [Yahoo! Finance]
5/23
07:00 am
tngx
Tango Therapeutics Announces Discontinuation of TNG348 Program
Medium
Report
Tango Therapeutics Announces Discontinuation of TNG348 Program
5/9
08:17 am
tngx
Tango Therapeutics, Inc. (NASDAQ: TNGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
Low
Report
Tango Therapeutics, Inc. (NASDAQ: TNGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
5/8
07:00 am
tngx
Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
Low
Report
Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
4/30
03:43 am
tngx
MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2024 [Yahoo! Finance]
Low
Report
MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2024 [Yahoo! Finance]
4/4
08:03 am
tngx
Tango Therapeutics, Inc. (NASDAQ: TNGX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Medium
Report
Tango Therapeutics, Inc. (NASDAQ: TNGX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
4/1
04:48 pm
tngx
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/20
08:08 am
tngx
Tango Therapeutics, Inc. (NASDAQ: TNGX) had its price target raised by analysts at HC Wainwright from $16.00 to $17.00. They now have a "buy" rating on the stock.
Medium
Report
Tango Therapeutics, Inc. (NASDAQ: TNGX) had its price target raised by analysts at HC Wainwright from $16.00 to $17.00. They now have a "buy" rating on the stock.
3/18
06:35 pm
tngx
Tango Therapeutics, Inc. (NASDAQ: TNGX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $18.00 price target on the stock.
Medium
Report
Tango Therapeutics, Inc. (NASDAQ: TNGX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $18.00 price target on the stock.